{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:11:39Z","timestamp":1788826299223,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The European Medicines Agency (EMA) is an institution of the European Union (EU), responsible for the authorization and pharmacovigilance of medicinal products. In our study, we present a systematic analysis of the 1,985 centralized EMA marketing authorization procedures (MAP) between 1995 and 2025. The analysis mainly includes EMA marketing authorizations, withdrawals of marketing authorizations, and revocations of marketing authorizations or refusals of drug applications. With regard to the analysis period, it is evident that the number of marketing authorizations recommended by the EMA increased significantly between 1996 (first fully published evaluation year) and 2025. Among the active substances (International Nonproprietary Names, INNs) in centralized EMA MAPs, clopidogrel and denosumab are the most frequently represented. On the other hand, antineoplastic agents and immunosuppressants are the most common therapeutic subgroups according to the Anatomical Therapeutic Chemical Classification (ATC) in MAPs. Notably, special MAPs for medicines such as generics, biosimilars, and medicines for the treatment of rare diseases (orphan medicines) account for more than 30% of MAPs. Our analysis shows that the development of centralized EMA MAPs is influenced by multiple factors such as medical need, regulatory framework, the economic potential of medicines, and patent law considerations. Our analysis provides a comprehensive overview of these procedures and may help identify potential obstacles and opportunities for their further development.<\/jats:p>","DOI":"10.1007\/s00210-026-05887-5","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:06:23Z","timestamp":1788825983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of marketing authorizations, withdrawals, and refusals by the European Medicines Agency (EMA): trends in approval procedures 1995\u20132025"],"prefix":"10.1007","author":[{"given":"Florian","family":"Hitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"5887_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.06.018","author":"N Amaouche","year":"2018","unstructured":"Amaouche N, Casaert Salom\u00e9 H, Collignon O, Santos MR, Ziogas C (2018) Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes. Drug Discov Today. https:\/\/doi.org\/10.1016\/j.drudis.2018.06.018","journal-title":"Drug Discov Today"},{"key":"5887_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120","author":"J Ambrosioni","year":"2026","unstructured":"Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, Mussini C, Marzolini C, Nielsen SD, B\u00e9guelin C, Welch S, Koval A, Mendao L, Bamford A, Calmy A, Guaraldi G, Oprea C, Mart\u00ednez E, Rockstroh JK, The EACS GB (2026) Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. HIV Med. https:\/\/doi.org\/10.1111\/hiv.70120","journal-title":"HIV Med"},{"key":"5887_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2026.104996","author":"LJ Bindel","year":"2026","unstructured":"Bindel LJ, Seifert R (2026) US post-marketed drug removals: analysis of discontinued and withdrawn drugs. J Pharmacol Exp Ther. https:\/\/doi.org\/10.1016\/j.jpet.2026.104996","journal-title":"J Pharmacol Exp Ther"},{"key":"5887_CR4","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2025a) Generische Zulassung. https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Zulassung\/Zulassungsarten\/Generische-Zulassung\/_node.html. Accessed 30 Jul 2025"},{"key":"5887_CR5","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2025b) Zulassung von Biosimilars. https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Zulassung\/Zulassungsarten\/Zulassung-von-Biosimilars\/_node.html. Accessed 30 Jul 2025"},{"key":"5887_CR6","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2025c) Orphan drugs.\u00a0https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Kooperationen-und-Projekte\/Orphanet\/Orphanet-International\/Orphan-Drugs\/_artikel.html. Accessed 30 Jul 2025"},{"key":"5887_CR7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0393","author":"D Dubrall","year":"2018","unstructured":"Dubrall D, Schmid M, Ale\u0161ik E, Paeschke N, Stingl J, Sachs B (2018) Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.2018.0393","journal-title":"Dtsch Arztebl Int"},{"key":"5887_CR8","unstructured":"European Agency for the Evaluation of Medicinal Products, Strachan Heppell (1996) First general report on the activities of the European Agency for the Evaluation of Medicinal Products.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/annual-report-european-agency-evaluation-medicinal-products-1995-en.pdf. Accessed 15 Dec 2025"},{"key":"5887_CR9","unstructured":"European Medicines Agency (EMA) (2015) European Medicines Agency 1995-2015 - Working together for safe and effective medicines.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/european-medicines-agency-1995-2015-working-together-safe-and-effective-medicines_en.pdf. Accessed 29 Jul 2025"},{"key":"5887_CR10","unstructured":"European Medicines Agency (EMA) (2020) Vom Labor zum Patienten: der Weg eines von der EMA bewerteten Arzneimittels.\u00a0https:\/\/www.ema.europa.eu\/de\/documents\/other\/laboratory-patient-journey-centrally-authorised-medicine_de.pdf. Accessed 23 Jul 2025"},{"key":"5887_CR11","unstructured":"European Medicines Agency (EMA) (2021) Medicines for use outside the European Union.\u00a0https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/medicines-use-outside-european-union. Accessed 22 Aug 2026"},{"key":"5887_CR12","unstructured":"European Medicines Agency (EMA) (2024) Authorisation of medicines.\u00a0https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines. Accessed 22 Aug 2026"},{"key":"5887_CR13","unstructured":"European Medicines Agency (EMA) (2025a) History of EMA.\u00a0https:\/\/www.ema.europa.eu\/en\/about-us\/history-ema. Accessed 10 Dec 2025"},{"key":"5887_CR14","unstructured":"European Medicines Agency (EMA) (2025b) How EMA evaluates medicines for human use.\u00a0https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines\/how-ema-evaluates-medicines-human-use#information-to-be-submitted. Accessed 23 Jul 2025"},{"key":"5887_CR15","unstructured":"European Medicines Agency (EMA) (2025c) Journey towards a roadmap for regulatory guidance on real-world evidence. https:\/\/www.ema.europa.eu\/en\/documents\/other\/journey-towards-roadmap-regulatory-guidance-real-world-evidence_en.pdf. Accessed 22 Aug 2026"},{"key":"5887_CR16","unstructured":"European Medicines Agency (EMA) (2026a) European Medicines Agency post-authorisation procedural advice for users of the centralised procedure.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf. Accessed 02 Jun 2026"},{"key":"5887_CR17","unstructured":"European Medicines Agency (EMA) (2026b) Download medicine data.\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/download-medicine-data. Accessed 30 May 2026"},{"key":"5887_CR18","unstructured":"European Medicines Agency (EMA), U. S. Food and Drug Administration (FDA) (2026) Guiding principles of good AI practice in drug development.\u00a0https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/2026-01-13_ai-guiding-principles_ema-fda_en.pdf. Accessed 22 Aug 2026"},{"key":"5887_CR19","doi-asserted-by":"crossref","unstructured":"Fricke U, Schwabe U (2010) Neue Arzneimittel 2009. In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-Report 2010. Springer Berlin Heidelberg, Berlin, pp 47\u2013126","DOI":"10.1007\/978-3-642-13380-0_2"},{"key":"5887_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00260-5","author":"M Garsen","year":"2021","unstructured":"Garsen M, Steenhof M, Zwiers A (2021) A decade of marketing authorization applications of anticancer drugs in the European Union: an analysis of procedural timelines. Ther Innov Regul Sci. https:\/\/doi.org\/10.1007\/s43441-021-00260-5","journal-title":"Ther Innov Regul Sci"},{"key":"5887_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010048","author":"I Gherghescu","year":"2020","unstructured":"Gherghescu I, Delgado-Charro MB (2020) The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13010048","journal-title":"Pharmaceutics"},{"key":"5887_CR22","doi-asserted-by":"publisher","unstructured":"Gibbons JB, Laber M, Bennett CL (2023) Humira: The first $20 billion drug. Am J Managed Care. https:\/\/doi.org\/10.37765\/ajmc.2023.89315","DOI":"10.37765\/ajmc.2023.89315"},{"key":"5887_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041320","author":"A Haerdtlein","year":"2023","unstructured":"Haerdtlein A, Debold E, Rottenkolber M, Boehmer AM, Pudritz YM, Shahid F, Gensichen J, Dreischulte T (2023) Which adverse events and which drugs are implicated in drug-related hospital admissions? A systematic review and meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12041320","journal-title":"J Clin Med"},{"key":"5887_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/978-3-642-13380-0_15","volume-title":"Arzneiverordnungs-Report 2010","author":"L Hein","year":"2010","unstructured":"Hein L (2010) Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-Report 2010. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 409\u2013423"},{"key":"5887_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-026-05443-1","author":"F Hitsch","year":"2026","unstructured":"Hitsch F, Seifert R (2026) Critical analysis of withdrawn drug applications in marketing authorization procedures of the European Medicines Agency (EMA) 2006\u20132024. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-026-05443-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5887_CR26","unstructured":"Kassen\u00e4rztliche Vereinigung Nordrhein (2026) Patentabl\u00e4ufe Arzneimittel.\u00a0https:\/\/www.kvno.de\/praxis\/beratung\/pharmakotherapieberatung\/arzneimittel\/patentablaeufe-arzneimittel. Accessed 04 Jun 2026"},{"key":"5887_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01936-y","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"5887_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04412-4","author":"F Lau","year":"2025","unstructured":"Lau F, Seifert R (2025) Comparison of drug approvals of the FDA and EMA between 2013 and 2023. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04412-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5887_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177371","author":"LM McNamee","year":"2017","unstructured":"McNamee LM, Walsh MJ, Ledley FD (2017) Timelines of translational science: from technology initiation to FDA approval. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0177371","journal-title":"PLoS ONE"},{"key":"5887_CR30","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S207246","author":"R Melsheimer","year":"2019","unstructured":"Melsheimer R, Geldhof A, Apaolaza I, Schaible T (2019) Remicade\u00ae (infliximab): 20 years of contributions to science and medicine. Biolog Targets Ther. https:\/\/doi.org\/10.2147\/BTT.S207246","journal-title":"Biolog Targets Ther"},{"key":"5887_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-662-68371-2_1","volume-title":"Arzneiverordnungs-Report 2023","author":"B M\u00fchlbauer","year":"2023","unstructured":"M\u00fchlbauer B, Ludwig W (2023) Arzneiverordnungen 2022 im \u00dcberblick. In: Ludwig W, M\u00fchlbauer B, Seifert R (eds) Arzneiverordnungs-Report 2023. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 3\u201328"},{"key":"5887_CR32","unstructured":"Pharma Fakten. e.V. (2020) Trotz Pandemie: Immunonkologika-Pipeline w\u00e4chst.\u00a0https:\/\/pharma-fakten.de\/grafiken\/1009-trotz-pandemie-immunonkologika-pipeline-waechst\/. Accessed 23 Jul 2025"},{"key":"5887_CR33","unstructured":"Pharma Fakten eV (2022) Onkologie: Eine Forschungsmaschinerie auf Hochtouren.\u00a0https:\/\/pharma-fakten.de\/grafiken\/onkologie-eine-forschungsmaschinerie-auf-hochtouren\/. Accessed 23 Jul 2025"},{"key":"5887_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-662-62168-4_1","volume-title":"Arzneiverordnungs-Report 2020","author":"U Schwabe","year":"2020","unstructured":"Schwabe U, Ludwig W (2020) Arzneiverordnungen 2019 im \u00dcberblick. In: Schwabe U, Ludwig W (eds) Arzneiverordnungs-Report 2020. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 3\u201341"},{"key":"5887_CR35","unstructured":"Statista.com (2024) Weltweite Forschungs- und Entwicklungsausgaben f\u00fchrender Pharmaunternehmen in den Jahren von 2016 bis 2030.\u00a0https:\/\/de.statista.com\/statistik\/daten\/studie\/263047\/umfrage\/weltweite-forschungs-und-entwicklungsausgaben-fuehrender-pharmaunternehmen\/. Accessed 18 Jul 2025"},{"key":"5887_CR36","unstructured":"Statistisches Bundesamt (Destatis) (2026) H\u00e4ufige Todesursachen in der EU-27.\u00a0https:\/\/www.destatis.de\/Europa\/DE\/Thema\/Bevoelkerung-Arbeit-Soziales\/Gesundheit\/_Grafik\/_Interaktiv\/haeufige-todesursachen.html. Accessed 01 Jun 2026"},{"key":"5887_CR37","unstructured":"The European Agency for the Evaluation of Medicinal Products (2000) Applications in Centralised Procedure 1995 to July 1999 \u2013an analysis of outcomes.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/other\/applications-centralised-procedure-1995-july-1999-analysis-outcomes_en.pdf. Accessed 20 Dec 2025"},{"key":"5887_CR38","unstructured":"U.S. Food and Drug Administration (FDA) (2026) Recalls Background and Definitions.\u00a0https:\/\/www.fda.gov\/safety\/industry-guidance-recalls\/recalls-background-and-definitions. Accessed 28 Jul 2026"},{"key":"5887_CR39","unstructured":"Verband Forschender Arzneimittelhersteller (VFA) (2026a) Leichte Erholung bei der Studienaktivit\u00e4t in Deutschland.\u00a0https:\/\/www.vfa.de\/de\/forschung-entwicklung\/forschungsstandort-deutschland\/klinische-studien-deutschland.html. Accessed 01 Jun 2026"},{"key":"5887_CR40","unstructured":"Verband Forschender Arzneimittelhersteller (VFA) (2026b) Medikamente gegen seltene Erkrankungen.\u00a0https:\/\/www.vfa.de\/de\/forschung-entwicklung\/pharmaforschung\/woran-wir-forschen\/orphan-drugs-medikamente-gegen-seltene-erkrankungen.html. Accessed 01 Jun 2026"},{"key":"5887_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-3-662-68371-2_4","volume-title":"Arzneiverordnungs-Report 2023","author":"S Vogler","year":"2023","unstructured":"Vogler S, Dicheva-Radev S, Panteli D, Busse R (2023) \u00dcberblick \u00fcber Ma\u00dfnahmen zur F\u00f6rderung des Einsatzes von Biosimilars in europ\u00e4ischen L\u00e4ndern. In: Ludwig W, M\u00fchlbauer B, Seifert R (eds) Arzneiverordnungs-Report 2023. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 63\u201395"},{"key":"5887_CR42","unstructured":"WHO Collaborating Centre for Drug Statistics (2026) ATC\/DDD Index 2026.\u00a0https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 05 Jun 2026"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05887-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:06:30Z","timestamp":1788825990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05887-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":42,"alternative-id":["5887"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05887-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      ) and officially registered as doctoral thesis project for Florian Hitsch. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable because publicly available information is used as data source.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines for editors acting as authors (\n                      \n                      ).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}